Expression of cancer cachexia-related factors in human cancer xenografts: An immunohistochemical analysis

Biomedical Research

Volumn 27, Issue 6, 2007, Pages 275-281

  Kamoshida, Shingo ^a   Watanabe, Kana ^a   Suzuki, Mai ^a   Mizutani, Yasuyoshi ^a   Sakamoto, Kazuki ^b   Sugimoto, Yoshikazu ^b   Oka, Toshinori ^b   Fukushima, Masakazu ^b   Tsutsumi, Yutaka ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; PROTEOLYSIS INDUCING FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC ALPHA2 GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CACHEXIA; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; CACHEXIA; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PROTEOGLYCANS; SEMINAL PLASMA PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MUS;

EID: 33846277628     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.27.275     Document Type: Article

References (43)

1. Balkwill F, Burke F, Talbot D, Tavernier J, Osborne R, Naylor S, Durbin H and Fiers W (1987) Evidence for tumour necrosis factor/cachectin production in cancer. Lancet ii, 1229-1232.
2. Beck SA, Groundwater P, Barton C and Tisdale MJ (1990) Alterations in serum lipolytic activity of cancer patients with response to therapy. Br J Cancer 62, 822-825.
3. Beutler B and Cerami A (1986) Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 320, 584-588.
4. Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ and Trayburn P (2004) Zinc-α 2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci USA 101, 2500-2505.
5. 2- glycoprotein in normal human epidermal and buccal epithelia. In Vivo 11, 271-274.
6. Cabal-Manzano R, Bhargava P, Torres-Duarte A, Marshall J, Bhargava P and Wainer IW (2001) Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer 84, 1599-1601.
7. Cariuk P, Lorite M, Todorov PT, Field W, Wigmore S and Tisdale MJ (1997) Induction of cachexia in mice by a product isolated from urine of cachectic cancer patients. Br J Cancer 76, 606-613.
8. Dhingra K, Sahin A, Emami K, Hortobagyi GN and Estrov Z (1998) Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat 48, 165-174.
9. 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. Eur J Cancer 29A, 1256-1260.
10. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL and Kurzrock R (2004) Cytokines in pancreatic carcinoma. Correlation with phenotypic characteristics and prognosis. Cancer 101, 2727-2736.
11. Fujimoto-Ouchi K, Tamura S, Mori K, Tanaka Y and Ishitsuka H (1995) Establishment and characterization of cachexia-inducing and non-inducing clones of murine colon 26 carcinoma. Int J Cancer 61, 522-528.
12. Groundwater P, Beck SA, Barton C, Adamson C, Ferrier IN and Tisdale MJ (1990) Alteration of serum and urinary lipolytic activity with weight-loss in cachectic cancer patients. Br J Cancer 62, 816-821.
13. Hale LP, Price DT, Sanchez LM, Demark-Wahnefried W and Madden JF (2001) Zinc α-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res 7, 846-853.
14. Hirai K, Hussey HJ, Barber MD, Price SA and Tisdale MJ (1998) Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 58, 2359-2365.
15. Inagalo K, Rodriguez V and Bodey GP (1974) Proceedings: causes of death in cancer patients. Cancer (Phila) 33, 568-573.
16. Iseki H, Kajimura N, Ohue C, Tanaka R, Akiyama Y and Yamaguchi K (1995) Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice. Jpn J Cancer Res 86, 562-567.
17. Jatoi A, Foster N, Wieland B, Murphy B, Nikcevich D, LaPlant B, Palcic MM and Baracos V (2006) The proteolysis-inducing factor: in search of its clinical relevance in patients with metastatic gastric/esophageal cancer. Dis Esophagus 19, 241-247.
18. Kajimura N, Iseki H, Tanaka R, Ohue C, Otsubo K, Gyoutoku M, Sasaki K, Akiyama Y and Yamaguchi K (1996) Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines. Cancer Chemother Pharmacol 38 (Suppl), S48-S52.
19. Kamohara H, Sakamoto K, Ishiko T, Mita S, Masuda Y, Abe T and Ogawa M (1994) Human carcinoma cell lines produce biologically active leukemia inhibitory factor (LIF). Res Commun Mol Pathol Pharmacol 85, 131-140.
20. Kawakami M and Cerami A (1981) Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med 154, 631-639.
21. Lorite MJ, Thompson MG, Drake JL, Carling G and Tisdale MJ (1998) Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer 78, 850-856.
22. McDevitt TM, Todorov PT, Beck SA, Khan SH and Tisdale MJ (1995) Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumours in mice and humans. Cancer Res 55, 1458-1463.
23. Metcalf D, Nicola NA and Gearing DP (1990) Effects of leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 76, 50-56.
24. Metcalf D (1991) The leukemia inhibitory factor (LIF). Int J Cell Cloning 9, 95-108.
25. Monitto CL, Dong SM, Jen J and Sidransky D (2004) Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clin Cancer Res 10, 5862-5869.
26. Mori M, Yamaguchi K and Abe K (1989) Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia. Biochem Biophys Res Commun 160, 1085-1092.
27. Mori M, Yamaguchi K, Honda S, Nagasaki K, Ueda M, Abe O and Abe K (1991) Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res 51, 6656-6659.
28. Okada S, Okusaka T, Ishii H, Kyogoku A, Yoshimori M, Kajimura N, Yamaguchi K and Kakizoe T (1998) Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol 28, 12-15.
29. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D. Vuocolo G, Wolfe A and Socher SH (1987) Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50, 555-563.
30. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr and Corey E (2003) Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97, 1211-1216.
31. Sánchez LM, Chirino AJ and Bjorkman P (1999) Crystal structure of human ZAG, a fat-depleting factor related to mHC molecules. Science 283, 1914-1919.
32. Scott HR, McMillan DC, Crilly A, McArdle CS and Milroy R (1996) The relationship between weight loss and interleukin 6 in non-small cell lung cancer. Br J Cancer 73, 1560-1562.
33. Socher SH, Friedman A and Martinez D (1988) Recombinant human tumor necrosis factor induces acute reductions in food intake and body weight in mice. J Exp Med 167, 1957-1962.
34. Socher SH, Martinez D, Craig JB, Kuhn G and Oliff A (1988) Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst 80, 595-598.
35. Soda K, Kawakami M, Kashii K and Miyata M (1995) Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. Int J Cancer 62, 332-336.
36. Strassmann G, Fong M, Kenney JS and Jacob CO (1992) Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89, 1681-1684.
37. Tamura S, Fujimoto-Ouchi K, Mori K, Endo M, Matsumoto T, Eda H, Tanaka Y, Ishitsuka H, Tokita H and Yamaguchi K (1995) Involvement of human interleukin 6 in experimental cachexia induced by a human uterine carcinoma xenograft. Clin Cancer Res 1, 1353-1358.
38. Todorov PT, Cariuk P, McDevitt TM, Coles B, Fearon K and Tisdale MJ (1996) Characterization of a cancer cachectic factor. Nature 379, 739-742.
39. Todorov PT, McDevitt TM, Cariuk P, Coles B, Deacon M and Tisdale MJ (1996) Induction of muscle protein degradation and weight loss by a tumor product. Cancer Res 56, 1256-1261.
40. Todorov PT, Deacon M and Tisdale MJ (1997) Structural analysis of a tumor-produced sulphated glycoprotein capable of initiating muscle protein degradation. J Biol Chem 272, 12279-12288.
41. Todorov PT, McDevitt TM, Meyer DJ, Ueyama H, Ohkubo I and Tisdale MJ (1998) Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res 58, 2353-2358.
42. Warren S (1932) The immediate causes of death in cancer. Am J Med Sci 184, 610-615.
43. Williams ML, Torres-Duarte A, Brant LJ, Bhargava P, Marshall J and Wainer IW (2004) The relationship between a urinary cachectic factor and weight loss in advanced cancer patients. Cancer Invest 22, 866-870.